Po-Hao Feng1, Chih-Teng Yu2, Chin-Yang Wu3, Meng-Jung Lee2, Wei-Hwa Lee3, Liang-Shun Wang4, Shu-Min Lin2, Jen-Fen Fu5, Kang-Yun Lee6, Tzung-Hai Yen7. 1. Division of Pulmonary Medicine, Department of Internal Medicine, Shuang Ho Hospital, Taipei Medical University Taipei, Taiwan ; Graduate Institue of Clinical Medical Science, College of Medicine, Chang Gung University Taoyuan, Taiwan ; Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University Taipei, Taiwan. 2. Division of Thoracic Medicine, Department of Internal Medicine, Chang Gung Medical Foundation, Linko Branch Taoyuan, Taiwan. 3. Department of Pathology, Shuang Ho Hospital, Taipei Medical University Taipei, Taiwan. 4. Division of Thoracic and Cardiovascular Surgery, Department of Surgery, Chang Gung Medical Fundation, Linko Branch Taoyuan, Taiwan. 5. Graduate Institue of Clinical Medical Science, College of Medicine, Chang Gung University Taoyuan, Taiwan. 6. Division of Pulmonary Medicine, Department of Internal Medicine, Shuang Ho Hospital, Taipei Medical University Taipei, Taiwan ; Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University Taipei, Taiwan. 7. Department of Internal Medicine, Chang Gung University College of Medicine Taoyuan, Taiwan.
Abstract
PURPOSE: Most of the patients with stage IIIA pN2 non-small cell lung cancer (NSCLC) develop recurrence after surgery. It is not clear whether post neoadjuvant chemotherapy tumor-associated macrophages is associated with recurrence. PATIENTS AND METHODS: Stage IIIA pN2 NSCLC patients underwent cisplatin/docetaxel neoadjuvant chemotherapy and surgery were retrospectively enrolled. Immunohistochemical staining of CD68 was used to identify macrophages in surgical resected stored tissues. RESULTS: The objective response rate of cisplatin/docetaxel was 68%, overall median disease-free survival (DFS) was 13.1 months and median overall survival (OS) 36.8. months. Multiple Cox regression analysis showed low total macrophage numbers and mediastinal lymph nodes downstaging were independent factors for longer DFS, whereas high islet/stromal macrophages ratio was an independent facto for OS. In patients downstaged to pN0, low total macrophage numbers was also associated with longer DFS. CONCLUSIONS: Low total macrophage number is an independent factor for better DFS in pN2 stage IIIA NSCLC patients receiving neoadjuvant chemotherapy and surgical resection, which association was kept in those downstaged to pN0. Further studies are warrant to confirm the predictive role of TAMs and their potential causative role in tumor recurrence.
PURPOSE: Most of the patients with stage IIIA pN2 non-small cell lung cancer (NSCLC) develop recurrence after surgery. It is not clear whether post neoadjuvant chemotherapy tumor-associated macrophages is associated with recurrence. PATIENTS AND METHODS: Stage IIIA pN2NSCLCpatients underwent cisplatin/docetaxel neoadjuvant chemotherapy and surgery were retrospectively enrolled. Immunohistochemical staining of CD68 was used to identify macrophages in surgical resected stored tissues. RESULTS: The objective response rate of cisplatin/docetaxel was 68%, overall median disease-free survival (DFS) was 13.1 months and median overall survival (OS) 36.8. months. Multiple Cox regression analysis showed low total macrophage numbers and mediastinal lymph nodes downstaging were independent factors for longer DFS, whereas high islet/stromal macrophages ratio was an independent facto for OS. In patients downstaged to pN0, low total macrophage numbers was also associated with longer DFS. CONCLUSIONS: Low total macrophage number is an independent factor for better DFS in pN2 stage IIIA NSCLCpatients receiving neoadjuvant chemotherapy and surgical resection, which association was kept in those downstaged to pN0. Further studies are warrant to confirm the predictive role of TAMs and their potential causative role in tumor recurrence.
Entities:
Keywords:
Lung cancer biology; immunochemistry; immunology
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: J A Roth; E N Atkinson; F Fossella; R Komaki; M Bernadette Ryan; J B Putnam; J S Lee; H Dhingra; L De Caro; M Chasen; W K Hong Journal: Lung Cancer Date: 1998-07 Impact factor: 5.705
Authors: Tomas J Welsh; Ruth H Green; Donna Richardson; David A Waller; Kenneth J O'Byrne; Peter Bradding Journal: J Clin Oncol Date: 2005-10-11 Impact factor: 44.544
Authors: R Rosell; J Gómez-Codina; C Camps; J Maestre; J Padille; A Cantó; J L Mate; S Li; J Roig; A Olazábal Journal: N Engl J Med Date: 1994-01-20 Impact factor: 91.245
Authors: D-W Kim; H S Min; K-H Lee; Y J Kim; D-Y Oh; Y K Jeon; S-H Lee; S-A Im; D H Chung; Y T Kim; T-Y Kim; Y-J Bang; S W Sung; J H Kim; D S Heo Journal: Br J Cancer Date: 2008-02-19 Impact factor: 7.640
Authors: Na Zhou; Yizhuang Zhang; Xuehui Zhang; Zhen Lei; Ruobi Hu; Hui Li; Yiqing Mao; Xi Wang; David M Irwin; Gang Niu; Huanran Tan Journal: Int J Mol Sci Date: 2015-05-26 Impact factor: 5.923